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Summary: For the determination of creatine kinase isoenzyme catalytic concentrations in serum two methods based
on immunological reactions are presented:
One method uses inhibiting antibodies, which selectively block the activity of creatine kinase M subunits ("Inhibition
Test*'). This test is used for routine measurements of creatine kinase MB catalytic concentration;
Another method uses precipitating antibodies, which allows a quantitative differentiation of creatine kinase isoenzymes
MM, MB and BB ("Precipitation Test"). This test is used as a control for the Inhibition Test for the possible presence of
creatine kinase BB activities in doubtful cases.
Procedures, specificity, correlation and application of these methods are discussed.
Quantitative Bestimmung der katalytischen Konzentrationen von Creatinkinase-Isoenzymen im Serum mit Hilfe
immunologischer Methoden
Zusammenfassung: Für die Bestimmung der katalytischen Konzentrationen von Creatinkinase-Isoenzymen im Serum
werden zwei Methoden auf immunologischer Basis beschrieben:
Eine Methode unter Verwendung inhibierender Antikörper, welche die Aktivität der Creatinkinase-M-Untereinheiten
selektiv hemmen („Hemmtest"). Diese Methode wird zur routinemäßigen Bestimmung der katalytischen Konzentra-
tionen von Creatinkinase-MB verwendet;
Eine zweite Methode unter Verwendung präzipitierender Antikörper, welche die quantitative Differenzierung der
Creatinkinäse-Isoenzyme MM, MB und BB erlaubt. Diese Methode wird in Zweifelsfällen als Kontrolle auf eventuelle
Creatinkinase-BB-Aktivitäten verwendet.
Die Methoden, ihre Spezifität, Korrelation und Anwendungsmöglichkeiten werden diskutiert.
Introduction MB ("myocardial type") and creatine kinase BB ("brain
type"). The differentiation of these isoenzymes has
Creatine kinase (CK; ATP: creatine phosphotransf erase, gained considerable interest, especially the measurement
EC 2.7.3-2) in the human organism occurs in the form
of dime« of the subunits M and B, respectively. There- '> J^^S^^^^^^
fore, 3 isoenzymes can be distinguished: creatine kinase gemeinschaft (Schwerpunktprogramm „Enzymdiagnostik"
MM ("skeletal muscle type"), the hybrid creatine kinase Pr 66/6).
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of creatine kinase MB catalytic concentration in serum as
a parameter of myocardial damage (1).
Several methods for the differentiation of creatine kinase
isoenzymes have been published:
Electrophoretic separation in polyacrylamide gel (2), in
agar gel (3), in agarose gel (4) und in cellulose acetate
(5), with subsequent activity measurement via NADPH
fluorescence or via reduction of tetrazolium salts to
formazanes.
Chromatographie separation on columns with ion ex-
change agarose (6) and with ion exchange cellulose (7);
on glass beads covered with ion exchange groups (8) or
on anion exchange polystyrene (8 a) with batch elution.
High pressure liquid chromatography separation on
anion exchange columns (9).
Differential activity measurement in the presence of
different substrates (10) and of different sulfhydryl
reactivators(ll).
Recently the use of precipitating antibodies has been
described (12, 13,14, 15,16).
In the laboratories of our group we have elaborated
routine methods for the immunological differentiation
of creatine kinase isoenzymes. In the following we
present two methods for the measurement of creatine
kinase isoenzyme catalytic concentrations in serum:
1. A method using inhibiting antibodies, which measures
the activity of creatine kinase B subunits present in the
sample ("Inhibition Test")' For this test inhibiting
antibodies (Inh-CK-M-antibodies) are employed, which
selectively and quantitatively block the activity of
creatine kinase M subunits. This test is used for the
measurement of serum creatine kinase MB catalytic
concentrations.
2. A method using precipitating antibodies, which
allows quantitative differentiation of creatine kinase
isoenzymes MM, MB, and BB, respectively ("Precipi-
tation Test"). In this test the precipitating antibodies
anti-Creatinkinase-MM and anti-Creatinkinase-BB are
employed. This test, in addition to its use in the
differentiation of all creatine kinase isoenzymes, is
proposed as a control in cases of suspected creatine
kinase BB activity in combination with the Inhibition
Test.
Procedure, specificity, correlation and application of
these methods are discussed.
Experimental Procedures and Results
Inhibition Test
Reagents
Preparation of creatine kinase MM human by a modified pro-
cedure according to Keutel et al. (17). Specific activity of the
enzyme used for immunization = 320 U/mg protein. Prepara-
tion of Inh-CK-M-antibodies according to W rzburg et al. (18)
and Neumeier et al. (19) in goats. Reagents and method for
measurement of creatine kinase catalytic concentration
according to the Recommendations of the German Society
for Clinical Chemistry (20). Reagents are used in form of
a test kit containing a quantity of inh-CK-M-antibodies, which
inhibit quantitatively per test about 1000 U/l, at least 800
U/l, creatine kinase MM (Merck-1-Test CK-MB, No. 14 300).
Procedure
Equilibrate serum and reagents at 25 °C. Add 2.00 ml buffer .
substrate solution plus 0.10 ml non hernolytic serum to one
bottle of coenzyme-enzyme^antibody reagent. Mix and
incubate for 7 minutes at 25 °C. Place in a 1 cm cuvette and
record absorbance for 5 minutes at 340 nm. Prepare and
measure a reagent blank without serum. Dilute sera with
creatine kinase catalytic concentrations over 800 U/l with
9 g/1 sodium chloride solution to catalytic concentrations below
800 U/l. Calculate activity from ΔΑ per 5 minutes after deduc-
tion of ΔΑ of the corresponding blank by multiplication with
the factor 667. This factor is derived as follows: Creatine
kinase B catalytic concentration =




e · d · 5
[U/l].
[U/l] =
ΔΑ/5 min χ — χ
0.1 6 3 0 0 - 1 - 5
The revised value for NADPH^onm is 6300 1 · mof1 · cm"1
(21). The result gives the catalytic concentration of CK-B
subunits present in the sample, if the catalytic concentration
is to be expressed as CK-MB, multiply the activity with the
factor of 2.
Model experiments
To demonstrate the degree of inhibition of creatine
kinase isoenzymes by Inh-CIGM-antibodies, model
experiments are performed on inactivated human sera,
to which measured amounts of purified human crea-
tine kinase isoenzymes are added. For the preparation
and specific activities of creatine kinase MM and BB
used, see chapter "Precipitation test, reagents".
Creatine kinase MB is prepared by reversible dissociation
of an equal mixture of creatine kinase MM plus BB in
3.6 mol/1 guanidinium chloride followed by Chromato-
graphie separation on DEAE agarose. Specific activity
of the creatine kinase MB preparation used = 330 U/mg
protein. The experiments are 5-fold determinations
with an intraserial CV of 1.99%. Table 1 contains the
results of these measurements. Within the limits of
error the following percentage of activity inhibition
is obtained: creatine kinase MM = 100%, creatine kinase
MB = 50%, creatine kinase BB = 0%. These figures are
valid in the total range of catalytic concentrations for
which this test has been conceived.
These figures, however, are mean values. Considering
the ± 2 SD range, the inhibition of creatine kinase MB
activity by Inh^CK-M-antibodies is between 45 and 56%
(not taking into account the larger variation with the
value of 18 U/l CK-MB). This range possibly represents
not only methodological errors, but also a difference
in the specific activity against creatine phosphate of
creatine kinase M and B subunits, respectively, or a
possible allosteric effect on the ereatine kinase B sub*
unit within the MB dimer effected by the binding of
the antibody to the M subunit. This problem is being
investigated.
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Tab. 1. Inhibition of creatine kinase isoenzyme catalytic concentrations by inhibiting creatine kinase M antibodies.
Inactivated human sera with addition of purified human creatine kinase isoenzymes. Mean ± 1 SD from 5 fold determinations.
Isoenzyme catalytic concentrations after
addition of human isoenzymes
fU/l]




















Further characterization of inhibiting antibodies
The inhibitory action of Inh-CK-M-antibodies can be
shown to be a primary interaction with the enzyme
molecule (no precipitation) by use of monovalent anti-
body fragments. Fab and Fc fragments are produced
from Inh-CK-M-antibody by a modified procedure
according to Porter (22). The inhibition of creatine
kinase MM activity by Inh-CK-M-antibody, Fab and Fc,
respectively, was measured at different concentrations
of these proteins. The results are presented in figure 1.
Fab fragments inhibit creatine kinase MM activity to
100%, the inhibition characteristics being the same
as with complete antibodies. Fc fragments yield no
inhibition of creatine kinase MM activity, as is to be
expected.
The influence of the animal species used to raise anti-
bodies on the specificity of Inh-CK^M-antibodies is
100 50 25 125 •63 3.2 16 OJB 0.4
Protein added [;ig]
0.1 0.05
Fig. 1. Inhibition of creatine kinase MM catalytic concentra-
tion by Inh-CK-M-antibodies and antibody fragments.
·—· Inh-GK-M-antibody IgG
ο—o F b fragments
α—o Fc fragments
shown in figure 2. The inhibition of creatine kinase MB
activity by antibodies from different animal species is
plotted against the antibody concentration. Only goat
antibodies yield 50% inhibition of creatine kinase MB
activity, this value being constant over a broad concen-
tration range. Rabbit and sheep antibodies at high con-
centrations inhibit creatine kinase MB activity by more
than 50%, which means that besides creatine kinase M
subunit activity, B subunit activity is also partially
inhibited.
The influence of the antigen used for immunization on
the specificity of the resulting antibodies is shown in
figure 3. The inhibition of creatine kinase MB activity-
is plotted against the antibody concentration. Besides
human creatine kinase MM, creatine kinase MM from
rhesus skeletal muscle also gives rise to antibodies in the
goat, which inhibit human creatine kinase MB by 50%.





1:1 1:2 1:8 1:32 1:128 1:512
Dilutions of inhibiting anti-creatine kinase M IgG (2-fold)
Fig. 2. Inhibition of creatine kinase MB (catalytic concentra-
tion 450 TJ/1) by anti-creatine kinase-M-antibodies raised
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Dilutions of inhibiting anti-creatine kinase MIgG (2- fo ld)
Precipitation Test
Reagents
Creatine kinase MM from skeletal muscle and of creatine kinase
BB from bran tissue are prepared by a modified version of
the method accprding to Keutel et al. (17). Specific activities
of creatine kinase MM = 320 U/mg protein, of creatine kinase
BB = 292 U/mg protein. Precipitating antisera are prepared
according to Neumeieret al. (16). The antisera are anti-Creatin-
kinase-MM (vom Hammel) (Merck No. 11 642) and anti-Creatin-
kinase-BB (vom Hammel) (Merck No. 11 643).
Borate buffer pH 8.4: dissolve 0.1 mol boric acid, 0.025 mol
disodium tetraborate χ 10 H2O and 0.075 mol NaCl in distilled
water to give 1 liter. Polyethylene glycol/n-acetyl cysteine
(PEG-NAC): dissolve 12 g polyethylene glycpl 6000 (Merck
Schuchardt No. 80 7491) and 0.653 g N-acetyl cysteine (Merck
No. 12 422) in 100 ml borate buffer, Reagents and method for
measurement of creatine kinase catalytic concentration are
according to the Recommendations of the German Society for
Clinical Chemistry (20) in the form of a test kit (Merck-1-Test
CK No. 3381).
Fig. 3. Inhibition of creatine kinase MB by anti-creatine kinase-





other species (rabbit, pig) give no adequate cross reaction
with the human enzyme (not shown in the figure).
Procedure
The precipitation test is performed according to Prellwitz
et al. (23) in a modification of the procedure described by
Jockers et al. (14,15), Prellwitz et al. (13) and Neumeier et al.
(16). The principle of the test is outlined in figure 4. Samples
with high creatine kinase catalytic concentrations are diluted
with bqrate buffer to a total creatine kinase catalytic concen-
tration in the range 70-90 U/l. Pipette tests according to
table 2. Incubate samples 1 hour at 37 °C plus overnight at
4 °C. Centrifuge samples at high speed. Take 0.10 ml from
clear supernatants for measurement in 3 fold deterfnina-
Precision
Measurements of creatine kinase MB catalytic concen-
tration in control samples (pooled sera of patients with
myocardial infarction and myocardial extracts) give the
following results:
Intraserial precision:
CV= 13% at 13 U/l,
CV= 5% at 32 U/l,
CV= 2% at 72 U/l (18).
Precision from day to day:
χ = 36 U/l, SD = 3.0 U/l, CV = 8.3%, n = 27 (18),
χ = 46 U/l, SD = 2.5 U/l, CV = 5.5%, n = 14 (19).
Long term precision in serum:
χ = 33 U/l, SD = 5.1 U/l, CV = 6.9%, n = 94 (23).
Long term precision in myocardial extracts:
χ = 174 U/l, SD = 11.8 U/l, CV = 6,7%, n = 41 (23).
Performing the test with double determinations plus
deduction of the reagent blank, creatine kinase MB
catalytic concentrations of 3 U/l can be distinguished
from zero level (95% niveau) (18). Performing the test
with single determinations without measurement of
the reagent blank, creatine kinase MB catalytic con-
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M-l anti- \-*-\ anti- l2—l anti-CK 88
V^J CK BB V^y CK MM \J +anti-CK MM
i ....... l ^ · ' ·· ,
incubate, Centrifuge
Measure creatine kinase catalytic concentrations in supernatants
1
Total CK CK MM CK BB




Fig. 4. Scheme for measurement of creatine kinase isoenzyme
catalytic concentrations with the Precipitation Test.
PEONAC = Polyethylene glycol-N-acetyl cysteine solu-
tion, see text.
CK = creatine kinase.
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tions. Calculate catalytic concentrations of the isoenzymes
according to the following scheme (see tab. 2):
albumin. For the preparation and specific activities
of the creatine kinase isoenzymes used, see sections
A = CK-MM + CK-MB + CK-BB = total creatine kinase "Precipitation Test, reagents" and "Inhibition Test,
Supernatant B = CK-MM model experiments". The results are summarized in
Supernatant D = CK-BB ^ figure 5 Jhe isoenzyme activities added to the different
Total CK - (CK-MM + CK-BB) - CK-MB mixtures are recovered within the limits of experi-
mental error.
Tab. 2. Pipetting scheme for measurement of creatine kinase isoenzyme catalytic concentrations with the Precipitation Test.
A B
Measurement of total creatine Measurement of supernatant
































Final concentration of polyethylene glycol (PEG) in test = 30 g/1
Final concentration of N-Acetyl cysteine (NAC) in test = 10 mmol/l
Dilution factor = 1.6
Model Experiments
Model experiments showing the differentiation of
Creatine kinase isoenzymes are performed in solutions
of purified human isoenzymes in 50 g/1 human serum
Precision
Measurement of creatine kinase MM catalytic concentra-









Fig. 5. Immuno precipitation of creatine kinase isoenzyme mixtures with the Precipitation Test,
a. Mixtures of creatine kinase MM and MB in different ratios.
catalytic concentrations added f U/l]
CK-MM CK-MB











b. Mixtures containing creatine kinase BB
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n = 10 (14). Measurement of creatine kinase MB
catalytic concentrations in serum: CV in the range of
10-20% (14, 16), this high value resulting from calcu-
lation of catalytic concentrations as difference values.
the activity of all creatine kinase B subunits present in
the sample is measured after inhibition of the creatine
kinase M subunit activity, differentiation between crea-
tine kinase MB and BB is not possible.
Comparison of Methods
Parallel measurements with the Inhibition Test and the
Precipitation Test of creatine kinase MB catalytic con-
centrations are performed in sera of patients suffering
from myocardial infarction and other diseases. The
results are presented as a correlation plot in figure 6.
The values measured with the Inhibition Test average
11 % higher than the values measured with the Preci-
pitation Test.
From the aspect of methodology two points are impor-
tant for the Inhibition Test: With respect to the reagents,
it is possible to use antisera raised against the enzyme
from rhesus monkey skeletal muscle, as well as anti-
bodies against human creatine kinase MM. Considering
test precision, the small absorbance differences measured
in sera with low creatine kinase MB catalytic concentra-
tions necessitate careful control of the known factors
interfering with creatine kinase catalytic concentration











0 40 80 120 160 200
Catalytic concentration of creatine kinase MB
(Precipitation test) [U/ l ]
Fig. 6. Correlation of creatine kinase MB catalytic concentra-
tions measured in parallel with Inhibition Test and Pre-
cipitation Test.
Human sera, n = 73
y = 3.90 + 1.llx
syx = ± l l U/l, r = 0.97.
Discussion
The two methods described here for measurement of
creatine kinase isoenzyme catalytic concentrations utilize
different aspects of the antigen-antibody-reaction:
The Inhibition Test is based on the primary immiirio-
logical reaction, the binding of antibodies to the enzyme
protein with concurrent inhibition of enzymatic activity.
This reaction mechanism has been proved by use of
monovalent antibody fragments, which show equal
enzyme.inhibition. Utilization of the primary irnmuno-
logical reaction leads to a short reaction time. Because
The Precipitation Test represents in immunological
terms a secondary reaction, the formation of a cross
linked insoluble immuno precipitate. This leads to a
long reaction time, but the differentiation of all creatine
kinase isoenzymes is possible. Measurement of creatine
kinase MM and BB catalytic concentrations yields results
with standard deviations in the usual range; measurement
of creatine kinase MB catalytic concentrations, however,
yields results with very large standard deviation, caused
by error multiplication in the difference calculation.
The principles of both tests outlined above lead to their
application in creatine kinase isoenzyme differentiation:
The Inhibition Test is used for fast and quantitative
measurement of creatine kinase MB catalytic concen-
trations in serum. Prerequisite for this use is the fact
that creatine kinase BB activities never or only rarely
occur in serum. The debate about the frequency of
occurrence of creatine kinase BB activities in serum
(23—33) is approaching the point where it is accepted
that creatine kinase BB activities in serum are found only
in exceptional cases. In the authors' investigations,
confirmed creatine kinase BB activities have been ob-
served in 2 out of about 15 000 routine measurements.
The specificity of the Inhibition Test will not be im-
paired significantly, therefore, by creatine kinase BB.
The Precipitation Test can be used in doubtful cases as a
safety check on the Inhibition Test. Because the preci-
pitating antiserum anti-CK-MM will precipitate creatine
kinase MM plus MB, it is possible to check with a single
precipitation, whether a suspected serum sample con^
tains creatine kinase BB activity or not.
The measured correlation of both methods is sufficient
for this suggested use of the Precipitation Test as safety
check for creatine kinase BB. In the Precipitation Test all
sera showing total creatine kinase catalytic concentrations
over 90 U/l have to be diluted. In view of the present
knowledge about the variation of creatine kinase catalytic
concentrations after dilution of sera, a better correlation
could not therefore be expected. '
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The results of measurements of creatine kinase iso-
enzyme catalytic concentrations in sera of patients with
different diseases using the tests described are being
published separately by several groups of authors (13—16,
18, 19,23,24,34,35).
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